Seoul National University Pituitary Disease Cohort Study

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

The purpose of this study is to investigate the treatment and natural history of pituitary disease. We have a longstanding interest in pituitary disease including acromegaly, central diabetes insipidus, and nonfunctioning pituitary adenoma. We will continue to follow patients and recruit new patients for treatment and follow-up. Blood and pituitary tumor tissue (when available through clinical care) will be saved for future analyses related to pituitary disease.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: No
View:

• Subjects for this study will be recruited if they are:

• Adults, male or female aged 18 years or older

• diagnosed with pituitary diseases such as acromegaly, Cushing's disease, hyperprolactinemia, nonfunctioning pituitary adenoma, pituitary stalk lesions, central diabetes insipidus, and craniopharyngiomas

Locations
Other Locations
Republic of Korea
Seoul National University Hospital
Recruiting
Seoul
Contact Information
Primary
Jung Hee Kim, M.D
jhkxingfu@gmail.com
82-2-2072-4073
Time Frame
Start Date: March 15, 2015
Estimated Completion Date: February 14, 2025
Participants
Target number of participants: 1600
Treatments
Acromegaly
Patients diagnosed with acromegaly
Cushing's disease
Patients diagnosed with Cushing's disease
Hyperprolactinemia/prolactinomas
Patients diagnosed with hyperprolactinemia/prolactinoma
Pituitary stalk lesions
Patients diagnosed with pituitary stalk lesions
Nonfunctioning pituitary adenomas
Patients diagnosed with nonfunctioning pituitary adenomas
Central diabetes insipidus
Patients diagnosed with central diabetes insipidus
Craniopharyngioma
Patients diagnosed with craniopharyngiomas
Others
Patients diagnosed with other suprasellar/parasellar lesions
Authors
Jung Hee Kim
Sponsors
Leads: Seoul National University Hospital

This content was sourced from clinicaltrials.gov

Similar Clinical Trials